Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.
EP. 1: Defining and Diagnosing Philadelphia Chromosome-Positive (Ph+) ALL
Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
EP. 2: Evolving Standard of Care for Patients Diagnosed with Ph+ ALL
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
EP. 3: Recent Updates from the PhALLCON Study
Medical experts highlight recent findings from the PhALLCON study.
EP. 4: Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
EP. 5: Notable Advancements in Treatment for ALL
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
EP. 6: Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL
With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer